Xu Bin, Liu Ning, Chen Shu-Qiu, Jiang Hua, Zhang Li-Jie, Zhang Xiao-Wen, Yang Yu, Sha Guo-Zhu, Liu Jing, Zhu Wei-Dong, Chen Ming
Department of Urology, Zhongda Hospital Affiliated to Southeast University, Nanjing, Jiangsu 210009, China.
Zhonghua Nan Ke Xue. 2016 Sep;22(9):771-776.
To explore the expression of I-5α-reductase (SRD5A1)and its prognostic role in prostate cancer .
Data about SRD5A1 were retrieved from the ONCOMINE database and the role of SRD5A1 in prostate cancer was analyzed.
Totally, 992 studies of different types relevant to the expression of SRD5A1 were identified in the ONCOMINE database. The SRD5A1 expression was statistically significant in 239 of the studies, overexpressed in 157 (11 in prostate cancer) and underexpressed in the other 82 (3 in prostate cancer). Eighteen of the studies, with 1 068 samples, addressed the expression of SRD5A1 in prostate cancer and normal tissues, which was significantly higher in the former than in the latter tissue (P<0.05). In 3 of the studies, the SRD5A1 expression was high in primary prostate cancer and increased with its metastasis (P<0.0 5). Two of the studies with prognostic data showed a higher rate of postoperative biochemical recurrence and a higher total mortality rate in the patients with a high than in those with a low expression of SRD5A1 (P<0.05).
SRD5A1 is highly expressed in prostate cancer, especially in metastatic and castration-resistant prostate cancer and its expression is associated with the prognosis of prostate cancer, which may be an important target of medication for prostate cancer.
探讨I-5α-还原酶（SRD5A1）在前列腺癌中的表达及其预后作用。
从ONCOMINE数据库检索SRD5A1的数据，并分析SRD5A1在前列腺癌中的作用。
在ONCOMINE数据库中总共鉴定出992项与SRD5A1表达相关的不同类型研究。其中239项研究中SRD5A1表达具有统计学意义，157项（前列腺癌中有11项）过表达，另外82项（前列腺癌中有3项）低表达。18项研究共1068个样本涉及SRD5A1在前列腺癌组织和正常组织中的表达，前者显著高于后者（P<0.05）。3项研究中，原发性前列腺癌中SRD5A1表达较高，且随转移而增加（P<0.05）。两项有预后数据的研究显示，SRD5A1高表达患者术后生化复发率和总死亡率高于低表达患者（P<0.05）。
SRD5A1在前列腺癌中高表达，尤其是在转移性和去势抵抗性前列腺癌中，其表达与前列腺癌预后相关，可能是前列腺癌治疗的重要药物靶点。
